JPMorgan raised the firm’s price target on Progyny (PGNY) to $25 from $23 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny’s Cautious Optimism Amid Challenges: A Hold Rating Analysis
- Progyny price target raised to $23 from $21 at Canaccord
- Progyny’s Earnings Call Highlights Robust Growth and Strategic Partnerships
- Strong Financial Performance and Market Trends Support Buy Rating for Progyny
- Progyny, Inc. Reports Record Q2 2025 Revenue